Alnylam Pharmaceuticals (ALNY)

Alnylam U.S., Inc. • Alnylam U.S. Holdings, Inc. • Alnylam UK Holdings Ltd. • Alnylam Securities Corporation • Sirna Therapeutics, Inc. • Alnylam Argentina SRL • Alnylam Australia Pty Ltd. • Alnylam Austria GmbH • Alnylam Brasil Farmaceutica Ltda. • Alnylam (Bermuda) Ltd. ...

IRS number

770602661

ALNY stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$361.33

Low target

$284.00

High target

$500.00

Latest filings (excl ownership)

View all

8-K

Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary

13 Feb 25

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress

13 Feb 25

8-K

Results of Operations and Financial Condition

31 Oct 24

Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity

1 Aug 24

Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity

1 Aug 24

8-K

Submission of Matters to a Vote of Security Holders

2 May 24

Transcripts

View all

ALNY

Earnings call transcript

2024 Q4

13 Feb 25

ALNY

Earnings call transcript

2024 Q3

31 Oct 24

ALNY

Earnings call transcript

2024 Q2

1 Aug 24

ALNY

Earnings call transcript

2024 Q1

2 May 24

ALNY

Earnings call transcript

2023 Q4

15 Feb 24

ALNY

Earnings call transcript

2023 Q3

2 Nov 23

ALNY

Earnings call transcript

2023 Q2

3 Aug 23

ALNY

Earnings call transcript

2023 Q2

3 Aug 23

ALNY

Earnings call transcript

2023 Q1

4 May 23

ALNY

Earnings call transcript

2022 Q4

23 Feb 23

Latest ownership filings

View all

Robert W. Hesslein

5 Mar 25

Kevin Joseph Fitzgerald

Notice of proposed sale of securities

4 Mar 25

144

Notice of proposed sale of securities

Financial summary

Financial statements Chart ALNY financial data

Quarter (USD)	Dec 24	Sep 24	Jun 24	Mar 24
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 23	Dec 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	968.65 mm	968.65 mm	968.65 mm	968.65 mm	968.65 mm	968.65 mm
Cash burn (monthly)	44.62 mm	(no burn)	64.65 mm	26.47 mm	31.55 mm	692.67 k
Cash used (since last report)	101.97 mm	n/a	147.76 mm	60.49 mm	72.12 mm	1.58 mm
Cash remaining	866.69 mm	n/a	820.89 mm	908.16 mm	896.54 mm	967.07 mm
Runway (months of cash)	19.4	n/a	12.7	34.3	28.4	1396.2

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

ALNY institutional ownership history Ownership history

98.8% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	583	562	+3.7%
Opened positions	92	105	-12.4%
Closed positions	71	66	+7.6%
Increased positions	233	213	+9.4%
Reduced positions	176	169	+4.1%

13F shares	Current	Prev Q	Change
Total value	27.84 tn	31.20 tn	-10.8%
Total shares	127.89 mm	121.54 mm	+5.2%
Total puts	646.49 k	1.12 mm	-42.3%
Total calls	754.50 k	1.23 mm	-38.5%
Total put/call ratio	0.9	0.9	-6.2%

Largest owners	Shares	Value	Change
Capital World Investors	16.60 mm	$3.91 tn	+0.6%
FMR	13.49 mm	$3.17 tn	-8.1%
Vanguard	12.73 mm	$3.00 tn	+0.8%
BlackRock	9.89 mm	$2.33 tn	+1.8%
Capital Research Global Investors	6.97 mm	$1.64 tn	+32.9%
REGN Regeneron Pharmaceuticals	4.44 mm	$1.05 tn	NEW
T. Rowe Price Investment Management	4.38 mm	$1.03 bn	+39.7%
Wellington Management	4.20 mm	$987.51 bn	-15.3%
Baillie Gifford & Co	4.04 mm	$950.71 bn	-17.3%
Dodge & Cox	3.54 mm	$833.06 bn	-2.3%

Largest transactions	Shares	Bought/sold	Change
REGN Regeneron Pharmaceuticals	4.44 mm	+4.44 mm	NEW
Capital International Investors	1.42 mm	-2.55 mm	-64.3%
Norges Bank	2.46 mm	+2.46 mm	NEW
Capital Research Global Investors	6.97 mm	+1.72 mm	+32.9%
T. Rowe Price Investment Management	4.38 mm	+1.25 mm	+39.7%
FMR	13.49 mm	-1.19 mm	-8.1%
Baillie Gifford & Co	4.04 mm	-846.74 k	-17.3%
Wellington Management	4.20 mm	-756.72 k	-15.3%
Qube Research & Technologies	485.26 k	+333.10 k	+218.9%
Marshall Wace	378.65 k	+315.18 k	+496.6%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ALNY insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
4 Mar 25	Pushkal Garg	Common Stock	Sell	Dispose S	No	Yes	242.7	120	29.12 k	24,542
4 Mar 25	Pushkal Garg	Common Stock	Sell	Dispose S	No	Yes	241.6	198	47.84 k	24,662
4 Mar 25	Pushkal Garg	Common Stock	Sell	Dispose S	No	Yes	240.92	343	82.64 k	24,860
4 Mar 25	Pushkal Garg	Common Stock	Sell	Dispose S	No	Yes	239.25	147	35.17 k	25,203
4 Mar 25	Kevin Joseph Fitzgerald	Common Stock	Sell	Dispose S	No	Yes	242.93	71	17.25 k	13,501
4 Mar 25	Kevin Joseph Fitzgerald	Common Stock	Sell	Dispose S	No	Yes	241.68	324	78.30 k	13,572
4 Mar 25	Kevin Joseph Fitzgerald	Common Stock	Sell	Dispose S	No	Yes	240.95	328	79.03 k	13,896
4 Mar 25	Kevin Joseph Fitzgerald	Common Stock	Sell	Dispose S	No	Yes	239.24	121	28.95 k	14,224
3 Mar 25	Yvonne Greenstreet	Common Stock	Sell	Dispose S	No	No	248.36	4	993.44	98,635
3 Mar 25	Yvonne Greenstreet	Common Stock	Sell	Dispose S	No	No	247.35	23	5.69 k	98,639